论文部分内容阅读
目的:探索p16蛋白表达与肺癌(LC)的关系。方法:应用免疫组织化学技术(S-P法)检测143例LC组织中p16蛋白的表达。结果:LC中p16蛋白表达阳性率为59.37%,其中腺癌(AC)为63.19%、鳞状细胞癌(SCC)为60.28%、腺鳞癌(ASC)为55.11%、小细胞癌(SC)为26.00%、肺泡细胞癌(BAC)为74.52%。p16蛋白阳性表达率在SC与AC、SCC及BAC比较,其差异有高度显著性(P<0.01);ASC与AC、SC及BAC,有转移的原发癌与其淋巴结的转移性癌及无转移性癌的原发癌比较,其差异有显著性(P<0.05)。结论:p16蛋白可能是LC预后判定的重要指标之一
Objective: To explore the relationship between p16 protein expression and lung cancer (LC). Methods: Immunohistochemical technique (S-P method) was used to detect the expression of p16 protein in 143 LC tissues. Results: The positive rate of p16 protein expression in LC was 59.37%, among which adenocarcinoma (AC) was 63.19%, squamous cell carcinoma (SCC) was 60.28%, and adenosquamous carcinoma (ASC) was 55.11. %, small cell carcinoma (SC) was 26.00%, and alveolar cell carcinoma (BAC) was 74.52%. The positive expression rate of p16 protein in SC was significantly higher than that in AC, SCC, and BAC (P<0.01); ASC and AC, SC, and BAC, metastatic carcinoma with metastatic primary cancer and its lymph nodes. There was a significant difference in the primary cancer without metastatic carcinoma (P<0.05). Conclusion: p16 protein may be one of the important indicators for the prognosis of LC